Press Releases

January 6, 2021 at 8:00 AM EST

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor Conference

SAN DIEGO --(BUSINESS WIRE)--Jan. 6, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version 140.7 KB
January 4, 2021 at 7:01 AM EST

Summary Toggle Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

Phase 2 study to be conducted in the U.S. and Singapore , and will evaluate both single dose and two dose priming regimens of ARCT-021 in up to 600 participants Anticipate interim Phase 2 data in early 2021; targeting global Phase 3 study start in Q2 2021 which could allow application for emergency

PDF Version
December 30, 2020 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

SAN DIEGO --(BUSINESS WIRE)--Dec. 30, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
December 28, 2020 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

Phase 1/2 data demonstrates favorable tolerability; immunogenicity observed in 100% (44/44) of vaccinated subjects receiving 7.5 µg single dose & 5 µg single and prime-boost regimens In primate challenge model, ARCT-021 demonstrates protection following both single dose and prime-boost regimens In

PDF Version 273.2 KB
December 7, 2020 at 11:30 PM EST

Summary Toggle Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

SAN DIEGO --(BUSINESS WIRE)--Dec. 7, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases,

PDF Version
December 7, 2020 at 4:33 PM EST

Summary Toggle Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO --(BUSINESS WIRE)--Dec. 7, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases,

PDF Version
December 7, 2020 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

SAN DIEGO --(BUSINESS WIRE)--Dec. 7, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
November 30, 2020 at 6:00 PM EST

Summary Toggle Arcturus Therapeutics to Present at Upcoming Investor Conference

SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

PDF Version
November 9, 2020 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

Investor conference call at 4:30 p.m. ET today SAN DIEGO --(BUSINESS WIRE)--Nov. 9, 2020-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and

PDF Version
November 9, 2020 at 7:00 AM EST

Summary Toggle Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

Based on interim Phase 1/2 results, a single 7.5 µg dose of ARCT-021, along with prime-boost regimens are selected to advance into later stage global clinical trials Seroconversion in majority of participants receiving doses in the range of 5 µg to 7.5 µg; Geometric Mean Titer (GMT) levels for

PDF Version